 | • レポートコード：MRC2102QY11802 • 出版社/出版日： / 2021年1月 • レポート形態：英文、PDF、137ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品、医療 |
| Single User | ￥600,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥900,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,200,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYリサーチ社の本調査レポートでは、世界の肺高血圧症治療薬市場について種類別（IK-3001、クエン酸シルデナフィルIMD、IK-7002、リオシグアト、SAR-407899、その他）、用途別（クリニック、病院、その他）、地域別（米国、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。市場予測データは新型コロナウイルスの影響を反映させました。 ・肺高血圧症治療薬市場の概要 ・世界の主要地域別肺高血圧症治療薬市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界の肺高血圧症治療薬市場規模2015-2026：種類別（IK-3001、クエン酸シルデナフィルIMD、IK-7002、リオシグアト、SAR-407899、その他） ・世界の肺高血圧症治療薬市場規模2015-2026：用途別（クリニック、病院、その他） ・肺高血圧症治療薬の米国市場規模2015-2020 ・肺高血圧症治療薬のヨーロッパ市場規模2015-2020 ・肺高血圧症治療薬の中国市場規模2015-2020 ・肺高血圧症治療薬の日本市場規模2015-2020 ・肺高血圧症治療薬の東南アジア市場規模2015-2020 ・肺高血圧症治療薬のインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 ・肺高血圧症治療薬の製造コスト分析 ・販売チャネル、流通業者、顧客 ・肺高血圧症治療薬の市場動向・機会・課題 ・調査の結論 |
Market Analysis and Insights: Global Pulmonary Hypertension Drug Market
The global Pulmonary Hypertension Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
Global Pulmonary Hypertension Drug Scope and Market Size
The global Pulmonary Hypertension Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Pulmonary Hypertension Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.
Segment by Type, the Pulmonary Hypertension Drug market is segmented into
IK-3001
Sildenafil Citrate IMD
IK-7002
Riociguat
SAR-407899
Others
Segment by Application, the Pulmonary Hypertension Drug market is segmented into
Clinic
Hospital
Others
The Pulmonary Hypertension Drug market is analysed and market size information is provided by regions (countries). Segment by Application, the Pulmonary Hypertension Drug market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Pulmonary Hypertension Drug Market Share Analysis
Pulmonary Hypertension Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Pulmonary Hypertension Drug business, the date to enter into the Pulmonary Hypertension Drug market, Pulmonary Hypertension Drug product introduction, recent developments, etc.
The major vendors covered:
Sanofi
Vectura Group plc
Bayer AG
Ikaria Inc.
Proreo Pharma AG
Vicore Pharma AB
Biolab Sanus Farmaceutica Ltda.
Hanmi Pharmaceuticals, Co. Ltd.
1 Pulmonary Hypertension Drug Market Overview
1.1 Pulmonary Hypertension Drug Product Scope
1.2 Pulmonary Hypertension Drug Segment by Type
1.2.1 Global Pulmonary Hypertension Drug Sales by Type (2020-2026)
1.2.2 IK-3001
1.2.3 Sildenafil Citrate IMD
1.2.4 IK-7002
1.2.5 Riociguat
1.2.6 SAR-407899
1.2.7 Others
1.3 Pulmonary Hypertension Drug Segment by Application
1.3.1 Global Pulmonary Hypertension Drug Sales Comparison by Application (2020-2026)
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Pulmonary Hypertension Drug Market Estimates and Forecasts (2015-2026)
1.4.1 Global Pulmonary Hypertension Drug Sales Growth Rate (2015-2026)
1.4.2 Global Pulmonary Hypertension Drug Revenue and Growth Rate (2015-2026)
1.4.3 Global Pulmonary Hypertension Drug Price Trends (2015-2026)
2 Pulmonary Hypertension Drug Estimate and Forecast by Region
2.1 Global Pulmonary Hypertension Drug Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Pulmonary Hypertension Drug Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Pulmonary Hypertension Drug Sales Market Share by Region (2015-2020)
2.2.2 Global Pulmonary Hypertension Drug Revenue Market Share by Region (2015-2020)
2.3 Global Pulmonary Hypertension Drug Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Pulmonary Hypertension Drug Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Pulmonary Hypertension Drug Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Pulmonary Hypertension Drug Estimates and Projections (2015-2026)
2.4.2 Europe Pulmonary Hypertension Drug Estimates and Projections (2015-2026)
2.4.3 China Pulmonary Hypertension Drug Estimates and Projections (2015-2026)
2.4.4 Japan Pulmonary Hypertension Drug Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Pulmonary Hypertension Drug Estimates and Projections (2015-2026)
2.4.6 India Pulmonary Hypertension Drug Estimates and Projections (2015-2026)
3 Global Pulmonary Hypertension Drug Competition Landscape by Players
3.1 Global Top Pulmonary Hypertension Drug Players by Sales (2015-2020)
3.2 Global Top Pulmonary Hypertension Drug Players by Revenue (2015-2020)
3.3 Global Pulmonary Hypertension Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pulmonary Hypertension Drug as of 2019)
3.4 Global Pulmonary Hypertension Drug Average Price by Company (2015-2020)
3.5 Manufacturers Pulmonary Hypertension Drug Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Pulmonary Hypertension Drug Players (Opinion Leaders)
4 Global Pulmonary Hypertension Drug Market Size by Type
4.1 Global Pulmonary Hypertension Drug Historic Market Review by Type (2015-2020)
4.1.1 Global Pulmonary Hypertension Drug Sales Market Share by Type (2015-2020)
4.1.2 Global Pulmonary Hypertension Drug Revenue Market Share by Type (2015-2020)
4.1.3 Global Pulmonary Hypertension Drug Price by Type (2015-2020)
4.2 Global Pulmonary Hypertension Drug Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Pulmonary Hypertension Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Pulmonary Hypertension Drug Revenue Forecast by Type (2021-2026)
4.2.3 Global Pulmonary Hypertension Drug Price Forecast by Type (2021-2026)
5 Global Pulmonary Hypertension Drug Market Size by Application
5.1 Global Pulmonary Hypertension Drug Historic Market Review by Application (2015-2020)
5.1.1 Global Pulmonary Hypertension Drug Sales Market Share by Application (2015-2020)
5.1.2 Global Pulmonary Hypertension Drug Revenue Market Share by Application (2015-2020)
5.1.3 Global Pulmonary Hypertension Drug Price by Application (2015-2020)
5.2 Global Pulmonary Hypertension Drug Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Pulmonary Hypertension Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Pulmonary Hypertension Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Pulmonary Hypertension Drug Price Forecast by Application (2021-2026)
6 United States Pulmonary Hypertension Drug Market Facts & Figures
6.1 United States Pulmonary Hypertension Drug Sales Market Share by Company (2015-2020)
6.2 United States Pulmonary Hypertension Drug Sales Market Share by Type (2015-2020)
6.3 United States Pulmonary Hypertension Drug Sales Market Share by Application (2015-2020)
7 Europe Pulmonary Hypertension Drug Market Facts & Figures
7.1 Europe Pulmonary Hypertension Drug Sales Market Share by Company (2015-2020)
7.2 Europe Pulmonary Hypertension Drug Sales Market Share by Type (2015-2020)
7.3 Europe Pulmonary Hypertension Drug Sales Market Share by Application (2015-2020)
8 China Pulmonary Hypertension Drug Market Facts & Figures
8.1 China Pulmonary Hypertension Drug Sales Market Share by Company (2015-2020)
8.2 China Pulmonary Hypertension Drug Sales Market Share by Type (2015-2020)
8.3 China Pulmonary Hypertension Drug Sales Market Share by Application (2015-2020)
9 Japan Pulmonary Hypertension Drug Market Facts & Figures
9.1 Japan Pulmonary Hypertension Drug Sales Market Share by Company (3015-3030)
9.2 Japan Pulmonary Hypertension Drug Sales Market Share by Type (2015-2020)
9.3 Japan Pulmonary Hypertension Drug Sales Market Share by Application (2015-2020)
10 Southeast Asia Pulmonary Hypertension Drug Market Facts & Figures
10.1 Southeast Asia Pulmonary Hypertension Drug Sales Market Share by Company (2015-2020)
10.2 Southeast Asia Pulmonary Hypertension Drug Sales Market Share by Type (2015-2020)
10.3 Southeast Asia Pulmonary Hypertension Drug Sales Market Share by Application (2015-2020)
11 India Pulmonary Hypertension Drug Market Facts & Figures
11.1 India Pulmonary Hypertension Drug Sales Market Share by Company (2015-2020)
11.2 India Pulmonary Hypertension Drug Sales Market Share by Type (2015-2020)
11.3 India Pulmonary Hypertension Drug Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Pulmonary Hypertension Drug Business
12.1 Sanofi
12.1.1 Sanofi Corporation Information
12.1.2 Sanofi Business Overview
12.1.3 Sanofi Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Sanofi Pulmonary Hypertension Drug Products Offered
12.1.5 Sanofi Recent Development
12.2 Vectura Group plc
12.2.1 Vectura Group plc Corporation Information
12.2.2 Vectura Group plc Business Overview
12.2.3 Vectura Group plc Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Vectura Group plc Pulmonary Hypertension Drug Products Offered
12.2.5 Vectura Group plc Recent Development
12.3 Bayer AG
12.3.1 Bayer AG Corporation Information
12.3.2 Bayer AG Business Overview
12.3.3 Bayer AG Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Bayer AG Pulmonary Hypertension Drug Products Offered
12.3.5 Bayer AG Recent Development
12.4 Ikaria Inc.
12.4.1 Ikaria Inc. Corporation Information
12.4.2 Ikaria Inc. Business Overview
12.4.3 Ikaria Inc. Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Ikaria Inc. Pulmonary Hypertension Drug Products Offered
12.4.5 Ikaria Inc. Recent Development
12.5 Proreo Pharma AG
12.5.1 Proreo Pharma AG Corporation Information
12.5.2 Proreo Pharma AG Business Overview
12.5.3 Proreo Pharma AG Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Proreo Pharma AG Pulmonary Hypertension Drug Products Offered
12.5.5 Proreo Pharma AG Recent Development
12.6 Vicore Pharma AB
12.6.1 Vicore Pharma AB Corporation Information
12.6.2 Vicore Pharma AB Business Overview
12.6.3 Vicore Pharma AB Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Vicore Pharma AB Pulmonary Hypertension Drug Products Offered
12.6.5 Vicore Pharma AB Recent Development
12.7 Biolab Sanus Farmaceutica Ltda.
12.7.1 Biolab Sanus Farmaceutica Ltda. Corporation Information
12.7.2 Biolab Sanus Farmaceutica Ltda. Business Overview
12.7.3 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Products Offered
12.7.5 Biolab Sanus Farmaceutica Ltda. Recent Development
12.8 Hanmi Pharmaceuticals, Co. Ltd.
12.8.1 Hanmi Pharmaceuticals, Co. Ltd. Corporation Information
12.8.2 Hanmi Pharmaceuticals, Co. Ltd. Business Overview
12.8.3 Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Products Offered
12.8.5 Hanmi Pharmaceuticals, Co. Ltd. Recent Development
13 Pulmonary Hypertension Drug Manufacturing Cost Analysis
13.1 Pulmonary Hypertension Drug Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Pulmonary Hypertension Drug
13.4 Pulmonary Hypertension Drug Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Pulmonary Hypertension Drug Distributors List
14.3 Pulmonary Hypertension Drug Customers
15 Market Dynamics
15.1 Pulmonary Hypertension Drug Market Trends
15.2 Pulmonary Hypertension Drug Opportunities and Drivers
15.3 Pulmonary Hypertension Drug Market Challenges
15.4 Pulmonary Hypertension Drug Market Restraints
15.5 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Pulmonary Hypertension Drug Sales (K Pcs) Growth Rate by Type (2020-2026) (US$ Million)
Table 2. Global Pulmonary Hypertension Drug Sales (K Pcs) Comparison by Application (2020-2026) (US$ Million)
Table 3. Global Market Pulmonary Hypertension Drug Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 4. Global Pulmonary Hypertension Drug Sales (K Pcs) by Region (2015-2020)
Table 5. Global Pulmonary Hypertension Drug Sales Market Share by Region (2015-2020)
Table 6. Global Pulmonary Hypertension Drug Revenue (US$ Million) Market Share by Region (2015-2020))
Table 7. Global Pulmonary Hypertension Drug Revenue Share by Region (2015-2020)
Table 8. Global Pulmonary Hypertension Drug Sales (K Pcs) Forecast by Region (2021-2026)
Table 9. Global Pulmonary Hypertension Drug Sales Market Share Forecast by Region (2021-2026)
Table 10. Global Pulmonary Hypertension Drug Revenue (US$ Million) Forecast by Region (2021-2026)
Table 11. Global Pulmonary Hypertension Drug Revenue Share Forecast by Region (2021-2026)
Table 12. Global Pulmonary Hypertension Drug (K Pcs) of Key Companies (2015-2020)
Table 13. Global Pulmonary Hypertension Drug Sales Share by Company (2015-2020)
Table 14. Global Pulmonary Hypertension Drug Revenue (US$ Million) by Company (2015-2020)
Table 15. Global Pulmonary Hypertension Drug Revenue Share by Company (2015-2020)
Table 16. Global Pulmonary Hypertension Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pulmonary Hypertension Drug as of 2019)
Table 17. Global Pulmonary Hypertension Drug Average Price (USD/Pcs) of Key Company (2015-2020)
Table 18. Manufacturers Pulmonary Hypertension Drug Manufacturing Sites and Area Served
Table 19. Manufacturers Pulmonary Hypertension Drug Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Main Points Interviewed from Key Pulmonary Hypertension Drug Players
Table 22. Global Pulmonary Hypertension Drug Sales (K Pcs) by Type (2015-2020)
Table 23. Global Pulmonary Hypertension Drug Sales Share by Type (2015-2020)
Table 24. Global Pulmonary Hypertension Drug Revenue (US$ Million) Market Share by Type (2015-2020)
Table 25. Global Pulmonary Hypertension Drug Price (K Pcs) by Type (2015-2020)
Table 26. Global Pulmonary Hypertension Drug Sales Share by Type (2021-2026)
Table 27. Global Pulmonary Hypertension Drug Revenue (US$ Million) Market Share by Type (2021-2026)
Table 28. Global Pulmonary Hypertension Drug Revenue Share by Type (2021-2026)
Table 29. Global Pulmonary Hypertension Drug Price (K Pcs) by Type (2021-2026)
Table 30. Global Pulmonary Hypertension Drug Sales (K Pcs) by Application (2015-2020)
Table 31. Global Pulmonary Hypertension Drug Sales Share by Application (2015-2020)
Table 32. Global Pulmonary Hypertension Drug Revenue (US$ Million) Market Share by Application (2015-2020)
Table 33. Global Pulmonary Hypertension Drug Price (K Pcs) by Application (2015-2020)
Table 34. Global Pulmonary Hypertension Drug Sales (K Pcs) by Application (2021-2026)
Table 35. Global Pulmonary Hypertension Drug Sales Share by Application (2021-2026)
Table 36. Global Pulmonary Hypertension Drug Revenue (US$ Million) Market Share by Application (2021-2026)
Table 37. Global Pulmonary Hypertension Drug Revenue Share by Application (2021-2026)
Table 38. Global Pulmonary Hypertension Drug Price (K Pcs) by Application (2021-2026)
Table 39. United States Pulmonary Hypertension Drug Sales (K Pcs) by Company (2015-2020)
Table 40. United States Pulmonary Hypertension Drug Sales Market Share by Company (2015-2020)
Table 41. United States Pulmonary Hypertension Drug Sales (K Pcs) by Type (2015-2020)
Table 42. United States Pulmonary Hypertension Drug Sales Market Share by Type (2015-2020)
Table 43. United States Pulmonary Hypertension Drug Sales (K Pcs) by Application (2015-2020)
Table 44. United States Pulmonary Hypertension Drug Sales Market Share by Application (2015-2020)
Table 45. Europe Pulmonary Hypertension Drug Sales (K Pcs) by Company (2015-2020)
Table 46. Europe Pulmonary Hypertension Drug Sales Market Share by Company (2015-2020)
Table 47. Europe Pulmonary Hypertension Drug Sales (K Pcs) by Type (2015-2020)
Table 48. Europe Pulmonary Hypertension Drug Sales Market Share by Type (2015-2020)
Table 49. Europe Pulmonary Hypertension Drug Sales (K Pcs) by Application (2015-2020)
Table 50. Europe Pulmonary Hypertension Drug Sales Market Share by Type (2015-2020)
Table 51. China Pulmonary Hypertension Drug Sales (K Pcs) by Company (2015-2020)
Table 52. China Pulmonary Hypertension Drug Sales Market Share by Company (2015-2020)
Table 53. China Pulmonary Hypertension Drug Sales (K Pcs) by Type (2015-2020)
Table 54. China Pulmonary Hypertension Drug Sales Market Share by Type (2015-2020)
Table 55. China Pulmonary Hypertension Drug Sales (K Pcs) by Application (2015-2020)
Table 56. China Pulmonary Hypertension Drug Sales Market Share by Application (2015-2020)
Table 57. Japan Pulmonary Hypertension Drug Sales (K Pcs) by Company (2015-2020)
Table 58. Japan Pulmonary Hypertension Drug Sales Market Share by Company (2015-2020)
Table 59. Japan Pulmonary Hypertension Drug Sales (K Pcs) by Type (2015-2020)
Table 60. Japan Pulmonary Hypertension Drug Sales Market Share by Type (2015-2020)
Table 61. Japan Pulmonary Hypertension Drug Sales (K Pcs) by Application (2015-2020)
Table 62. Japan Pulmonary Hypertension Drug Sales Market Share by Application (2015-2020)
Table 63. Southeast Asia Pulmonary Hypertension Drug Sales (K Pcs) by Company (2015-2020)
Table 64. Southeast Asia Pulmonary Hypertension Drug Sales Market Share by Company (2015-2020)
Table 65. Southeast Asia Pulmonary Hypertension Drug Sales (K Pcs) by Type (2015-2020)
Table 66. Southeast Asia Pulmonary Hypertension Drug Sales Market Share by Type (2015-2020)
Table 67. Southeast Asia Pulmonary Hypertension Drug Sales (K Pcs) by Type (2015-2020)
Table 68. Southeast Asia Pulmonary Hypertension Drug Sales Market Share by Application (2015-2020)
Table 69. India Pulmonary Hypertension Drug Sales (K Pcs) by Company (2015-2020)
Table 70. India Pulmonary Hypertension Drug Sales Market Share by Company (2015-2020)
Table 71. India Pulmonary Hypertension Drug Sales (K Pcs) by Type (2015-2020)
Table 72. India Pulmonary Hypertension Drug Sales Market Share by Type (2015-2020)
Table 73. India Pulmonary Hypertension Drug Sales (K Pcs) by Application (2015-2020)
Table 74. India Pulmonary Hypertension Drug Sales Market Share by Application (2015-2020)
Table 75. Sanofi Corporation Information
Table 76. Sanofi Description and Business Overview
Table 77. Sanofi Pulmonary Hypertension Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 78. Sanofi Pulmonary Hypertension Drug Product
Table 79. Sanofi Recent Development
Table 80. Vectura Group plc Corporation Information
Table 81. Vectura Group plc Description and Business Overview
Table 82. Vectura Group plc Pulmonary Hypertension Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 83. Vectura Group plc Pulmonary Hypertension Drug Product
Table 84. Vectura Group plc Recent Development
Table 85. Bayer AG Corporation Information
Table 86. Bayer AG Description and Business Overview
Table 87. Bayer AG Pulmonary Hypertension Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 88. Bayer AG Pulmonary Hypertension Drug Product
Table 89. Bayer AG Recent Development
Table 90. Ikaria Inc. Corporation Information
Table 91. Ikaria Inc. Description and Business Overview
Table 92. Ikaria Inc. Pulmonary Hypertension Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 93. Ikaria Inc. Pulmonary Hypertension Drug Product
Table 94. Ikaria Inc. Recent Development
Table 95. Proreo Pharma AG Corporation Information
Table 96. Proreo Pharma AG Description and Business Overview
Table 97. Proreo Pharma AG Pulmonary Hypertension Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 98. Proreo Pharma AG Pulmonary Hypertension Drug Product
Table 99. Proreo Pharma AG Recent Development
Table 100. Vicore Pharma AB Corporation Information
Table 101. Vicore Pharma AB Description and Business Overview
Table 102. Vicore Pharma AB Pulmonary Hypertension Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 103. Vicore Pharma AB Pulmonary Hypertension Drug Product
Table 104. Vicore Pharma AB Recent Development
Table 105. Biolab Sanus Farmaceutica Ltda. Corporation Information
Table 106. Biolab Sanus Farmaceutica Ltda. Description and Business Overview
Table 107. Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 108. Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Product
Table 109. Biolab Sanus Farmaceutica Ltda. Recent Development
Table 110. Hanmi Pharmaceuticals, Co. Ltd. Corporation Information
Table 111. Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 112. Hanmi Pharmaceuticals, Co. Ltd. Description and Business Overview
Table 113. Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Product
Table 114. Hanmi Pharmaceuticals, Co. Ltd. Recent Development
Table 115. Production Base and Market Concentration Rate of Raw Material
Table 116. Key Suppliers of Raw Materials
Table 117. Pulmonary Hypertension Drug Distributors List
Table 118. Pulmonary Hypertension Drug Customers List
Table 119. Pulmonary Hypertension Drug Market Key Trends
Table 120. Pulmonary Hypertension Drug Key Opportunities and Drivers
Table 121. Pulmonary Hypertension Drug Market Challenges
Table 122. Research Programs/Design for This Report
Table 123. Key Data Information from Secondary Sources
Table 124. Key Data Information from Primary Sources
List of Figures
Figure 1. Pulmonary Hypertension Drug Product Picture
Figure 2. Global Pulmonary Hypertension Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Pulmonary Hypertension Drug Market Share by Application in 2020 & 2026
Figure 6. Clinic Examples
Figure 7. Hospital Examples
Figure 8. Others Examples
Figure 9. Global Pulmonary Hypertension Drug Sales (K Pcs) Growth Rate (2015-2026)
Figure 10. Global Pulmonary Hypertension Drug Revenue (US$ Million) Growth Rate (2015-2026)
Figure 11. Global Pulmonary Hypertension Drug Price Trends Growth Rate (2015-2026) (USD/Pcs)
Figure 12. Global Pulmonary Hypertension Drug Revenue Market Share by Region: 2015 VS 2020
Figure 13. Global Pulmonary Hypertension Drug Revenue Market Share by Region: 2021 VS 2026
Figure 14. United States Pulmonary Hypertension Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 15. United States Pulmonary Hypertension Drug Sales (K Pcs) Growth Rate (2015-2026)
Figure 16. Europe Pulmonary Hypertension Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 17. Europe Pulmonary Hypertension Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 18. China Pulmonary Hypertension Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 19. China Pulmonary Hypertension Drug Sales (Million USD) and Growth Rate (2015-2026)
Figure 20. Japan Pulmonary Hypertension Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 21. Japan Pulmonary Hypertension Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 22. Southeast Asia Pulmonary Hypertension Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia Pulmonary Hypertension Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 24. India Pulmonary Hypertension Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 25. India Pulmonary Hypertension Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 26. Global 5 Largest Pulmonary Hypertension Drug Players Market Share by Revenue in Pulmonary Hypertension Drug 2015 & 2019
Figure 27. Pulmonary Hypertension Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 28. Global Pulmonary Hypertension Drug Revenue Share by Type (2015-2020)
Figure 29. Global Pulmonary Hypertension Drug Revenue Growth Rate by Type in 2015 & 2019
Figure 30. Global Pulmonary Hypertension Drug Revenue Share by Application (2015-2020)
Figure 31. Global Pulmonary Hypertension Drug Revenue Growth Rate by Application in 2015 & 2019
Figure 32. United States Pulmonary Hypertension Drug Sales Market Share by Type in 2019
Figure 33. United States Pulmonary Hypertension Drug Sales Market Share by Type in 2019
Figure 34. Europe Pulmonary Hypertension Drug Sales Market Share by Company in 2019
Figure 35. Europe Pulmonary Hypertension Drug Sales Market Share by Type in 2019
Figure 36. Europe Pulmonary Hypertension Drug Sales Market Share by Application in 2019
Figure 37. China Pulmonary Hypertension Drug Sales Market Share by Company in 2019
Figure 38. China Pulmonary Hypertension Drug Sales Market Share by Type in 2019
Figure 39. China Pulmonary Hypertension Drug Sales Market Share by Application in 2019
Figure 40. Japan Pulmonary Hypertension Drug Sales Market Share by Company in 2019
Figure 41. Japan Pulmonary Hypertension Drug Sales Market Share by Type in 2019
Figure 42. Japan Pulmonary Hypertension Drug Sales Market Share by Application in 2019
Figure 43. Southeast Asia Pulmonary Hypertension Drug Sales Market Share by Company in 2019
Figure 44. Southeast Asia Pulmonary Hypertension Drug Sales Market Share by Type in 2019
Figure 45. Southeast Asia Pulmonary Hypertension Drug Sales Market Share by Application in 2019
Figure 46. India Pulmonary Hypertension Drug Sales Market Share by Company in 2019
Figure 47. India Pulmonary Hypertension Drug Sales Market Share by Type in 2019
Figure 48. India Pulmonary Hypertension Drug Sales Market Share by Application in 2019
Figure 49. Key Raw Materials Price Trend
Figure 50. Manufacturing Cost Structure of Pulmonary Hypertension Drug
Figure 51. Manufacturing Process Analysis of Pulmonary Hypertension Drug
Figure 52. Pulmonary Hypertension Drug Industrial Chain Analysis
Figure 53. Channels of Distribution
Figure 54. Distributors Profiles
Figure 55. Porter's Five Forces Analysis
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
肺動脈性肺高血圧症（PAH）治療薬の世界市場レポート2020 Market Analysis and Insights: Global Pulmonary Arterial Hypertension (PAH) Drugs Market The global Pulmonary Arterial Hypertension (PAH) Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. Global Pulmonary Arterial Hypertens…- 特発性肺線維症治療薬の世界市場レポート2020 Market Analysis and Insights: Global Idiopathic Pulmonary Fibrosis Drug Market The global Idiopathic Pulmonary Fibrosis Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. Global Idiopathic Pulmonary Fibrosis Drug Scope and M…
- 肺塞栓症治療薬の世界市場レポート2020 Market Analysis and Insights: Global Pulmonary Embolism Drug Market The global Pulmonary Embolism Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. Global Pulmonary Embolism Drug Scope and Market Size The global Pulmonary E…
- 肺用ドラッグデリバリーデバイス/システムの世界市場レポート2020 Pulmonary Drug Delivery Devices/Systems include metered dose inhalers,dry powder inhalers,nebulizers and accessories. North America dominates the dominant drug delivery devices/systems market position. Major local pharmaceutical and medical device manufacturers, advanced medical infrastructure, popu…
- 肺用ドラッグデリバリーシステムの世界市場レポート2020 Pulmonary drug delivery systems are used to the treatment of various respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD), delivering locally acting drugs directly to their site of action. Advantages of pulmonary drug delivery systems over oral drugs is the excellent cap…